Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Continued Zepzelca Growth Across Second-Line SCLC Setting
Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date
On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader
Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition
23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020
2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion
DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021.
United-states
Ireland
Dublin
American
Jacqueline-kirby
Pharma-mar
Andrean-flynn
Oxybate-xyrem
Robert-iannone
Erwinaze-erwinase
Epidiolex-epidyolex
Bruce-cozadd